GlassScriptPhysician profile
Steven T Popper
NPI 1679849012
$4,244.11
in general payments reported to CMS, 2019-2025
15 companies · $336 in 2025
The $336 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $164 · 2020: $19.40 · 2021: $60.63 · 2022: $194 · 2023: $3,175 · 2024: $295 · 2025: $336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3,017 · Food and Beverage: $788.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3,017.38 |
| Food and Beverage | $788.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,281.76 | 2023-2024 | Da Vinci Surgical System |
| Glaxosmithkline, LLC. | $471.78 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Philips North America LLC | $110.07 | 2019-2025 | Vest Therapy Und |
| Genentech USA, INC. | $85.71 | 2021-2022 | |
| Inspire Medical Systems, INC. | $49.41 | 2024 | Inspire |
| Baxter Healthcare | $38.38 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Amgen INC. | $33.67 | 2023 | Tezspire |
| Insmed, INC. | $33.62 | 2021-2025 | |
| Actelion Pharmaceuticals US, INC. | $30.87 | 2019 | |
| Mylan Specialty L.P. | $25.98 | 2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.00 | 2023 | Ofev |
| Resmed Corp | $18.52 | 2019 | |
| Jazz Pharmaceuticals INC. | $17.95 | 2019 | |
| Genzyme Corporation | $15.00 | 2024 | |
| Pfizer INC. | $11.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Popper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.